Obaro Evuarherhe, Principal Consultant at Oxford PharmaGenesis, presents a paper, “Professional medical writing support and the quality, ethics and timeliness of clinical trial reporting: a systematic review”, published in Research Integrity and Peer Review.
Recorded 21 October 2019 at a MedComms Networking event in Oxford. Produced by NetworkPharma.tv
= = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = =
Professional medical writing support and the quality, ethics and timeliness of clinical trial reporting: a systematic review
Many authors choose to work with professional medical writers when reporting the results of clinical trials. We conducted a systematic review to examine the relationship between professional medical writing support (PMWS) and the quality, ethics and timeliness of publications reporting clinical trials.
Using terms related to ‘medical writer’ and ‘observational study’, we searched MEDLINE and Embase (no date limits), as well as abstracts and posters from meetings of the International Society for Medical Publication Professionals (ISMPP; 2014–2018). We also hand-searched the journals Medical Writing and The Write Stuff (2014–2018) and the bibliographies of studies identified in the electronic searches. We screened the results to identify studies that compared the quality, ethics and timeliness of clinical trial publications written with and without declared PMWS.
Our searches identified 97 potentially relevant studies, of which 89 were excluded during screening and full paper review. The remaining eight studies compared 849 publications with PMWS with 2073 articles developed without such support. In these eight studies, PMWS was shown to be associated with increased adherence to Consolidated Standards of Reporting Trials (CONSORT) guidelines (in 3/3 studies in which this was assessed), publication in journals with an impact factor (one study), a higher quality of written English (one study), and a lower likelihood of reporting non-pre-specified outcomes (one study). PMWS was not associated with increased adherence to CONSORT for Abstracts guidelines (one study) or with the impact of published articles (mean number of citations per year, mean number of article views per year and Altmetric score; one study). In studies that assessed timeliness of publication, PMWS was associated with a reduced time from last patient visit in clinical trials to primary publication (one study), whereas time from submission to acceptance showed inconsistent results (two studies).
This systematic review of eight observational studies suggests that PMWS is positively associated with measures of overall quality of reporting of clinical trials and may improve the timeliness of publication.
We are building a library of free webcasts, like this one, for the global MedComms Community and others at http://www.networkpharma.tv and we’d welcome your suggestions for new topics and speakers.
Full details of this MedComms Networking event are at http://medcommsnetworking.com/event_211019.html
Obaro’s presentation (PDF format) is at http://www.medcommsnetworking.com/presentations/evuarherhe_211019.pdf
Obaro’s Linkedin page is at https://www.linkedin.com/in/obaro-evuarherhe-5b3409a6/
More about Oxford PharmaGenesis can be found at http://www.pharmagenesis.com/
More about Open Pharma can be found at https://openpharma.blog/
Filming and technical direction by Mario Crispino, Freelance Cameraman & Editor
[For the avoidance of doubt: this video is intended to be freely accessible to all. Please feel free to share and use however you like. Cheers Peter Llewellyn, Director NetworkPharma Ltd and Founder of the MedComms Networking Community activity at http://www.medcommsnetworking.com]